Oligonucleotide Synthesis Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 4.90 Bn

Forecast Year, 2035

USD 12.65 Bn

CAGR, 2026 - 2035

9.95%

Report Coverage

Global

What is the Oligonucleotide Synthesis Market Size in 2026?

The global oligonucleotide synthesis market size accounted for USD 4.90 billion in 2025 and is predicted to increase from USD 5.39 billion in 2026 to approximately USD 12.65 billion by 2035, expanding at a CAGR of 9.95% from 2026 to 2035. The market is driven by growing investments by pharma companies in developing novel therapeutics, coupled with the surging prevalence of genetic disorders worldwide.

Key Takeaways

• North America led the market with 44% share in 2025.
• Asia Pacific is expected to rise with the highest CAGR during the forecast period.
• By type of product synthesized, the finished dosage forms segment held the largest share of the market in 2025.
• By type of product synthesized, the active pharmaceutical ingredients segment is expected to expand at a significant CAGR during the forecast period.
• By therapeutic area, the rare diseases segment held the largest share of 44% in the market in 2025.
• By therapeutic area, the cardiovascular disorders segment is expected to grow at a considerable CAGR between 2026 and 2035.
• By company size, the large and very large segment held the largest share of 70% in the market in 2025.
• By company size, the mid-sized segment is expected to rise with a robust CAGR during the forecast period.
• By scale of operation, the commercial segment held the highest share of 78% in the market and is expected to grow significantly during the forecast period.
• By type of oligonucleotide synthesized, the antisense oligonucleotide segment dominated with 58% share in the market in 2025.
• By type of oligonucleotide synthesized, the siRNA segment is expected to grow at a notable CAGR during the forecast period.
• By scale of operation, the commercial segment dominated the market in 2025.
• By end-users, the pharmaceutical/biopharmaceutical companies segment held the largest share of the market in 2025.

Market Overview

The oligonucleotide synthesis market is a prominent branch of the pharmaceutical sector. This market deals with delivering advanced solutions to enhance the synthesis of oligonucleotides. Oligonucleotide synthesis is a chemical process of developing custom DNA/RNA sequences (typically 3'-to-5') from nucleoside bases using the phosphonamidite method. This process involves a four-step cycle, including detritylation, capping, coupling, and oxidation. The growing focus of market players on advancing research and development of oligonucleotide therapies to enhance treatment methodology is boosting market expansion. This market is expected to expand significantly with the expansion of the biotech sector globally.

Major Market Trends

• Collaborations: Numerous biopharmaceutical brands are collaborating with genetic engineering companies to develop oligonucleotide therapeutics. For instance, in April 2025, Creyon Bio, Inc., collaborated with Eli Lilly and Company. This collaboration aims at accelerating the development of novel RNA-targeted oligonucleotide therapies for the treatment of rare and common diseases.
• Business Expansions: Various pharma companies are investing rapidly in opening new oligonucleotide manufacturing capacity in different parts of the world. For instance, in April 2024, ST Pharm invested around US$ 110 million. This investment is made to open an oligonucleotide manufacturing unit in Bandola, South Korea.
• Rising Prevalence of Cancers: The growing cases of cancers in different nations, such as the U.S., India, Germany, and the UAE, have increased the demand for oligonucleotide therapeutics. According to the American Cancer Society, around 324580 cases of new breast cancer are expected to be diagnosed in the U.S. during 2026.

What is the Significance of AI in the Oligonucleotide Synthesis Industry?

AI plays a significant role in the oligonucleotide synthesis industry by enhancing accuracy, efficiency, and speed throughout the design and production processes. AI helps in accelerating the drug discovery process, enhances clinical trial optimization, and improves supply chain management capabilities. Nowadays, oligonucleotide synthesis companies have started integrating AI into their manufacturing plants to enhance custom design, improve process optimization, and enable real-time monitoring. Overall, AI integration reduces costs, minimizes human error, and supports the growing demand for high-quality, customized oligonucleotides in the pharmaceutical and biotechnology sectors.

• In September 2025, Intellegens launched Alchemite. Alchemite is an AI-based platform designed to accelerate the process development of oligonucleotide therapies.

Market Scope

Segment Insights

Type of Product Synthesized Insights

Why Did the Finished Dosage Forms Segment Dominate the Market?

The finished dosage forms segment dominated the oligonucleotide synthesis market with the largest share in 2025. This is mainly due to the increased use of oligonucleotides for the production of cancer medicines. Additionally, the growing focus of the pharma companies in launching finished medicinal items for generating maximum profit margins is expected to accelerate the growth of this segment.

The active pharmaceutical ingredients segment is expected to grow at a significant CAGR during the forecast period. This is due to the increasing demand for API from the pharmaceutical sector to manufacture a wide range of oligonucleotide-based therapeutics. Additionally, the surging deployment of AI in the biopharmaceutical sector for deriving active pharmaceutical ingredients is contributing to segmental growth.

Therapeutic Area Insights

What Made Rare Diseases the Leading Segment in the Market?

The rare diseases segment led the oligonucleotide synthesis market by holding a major share in 2025. This is due to the increased prevalence of a wide range of rare diseases, such as cystic fibrosis, Huntington's disease, Duchenne muscular dystrophy, Haemophilia, and Ehlers-Danlos syndrome, driving the demand for oligonucleotide-based therapies. These therapies offer precision treatment where conventional drugs often fail, driving strong demand from pharmaceutical and biotech companies. Additionally, the rising focus of the pharma companies on using oligonucleotides for developing therapeutics to treat CREST syndrome and Evans syndrome is playing a prominent role in shaping the segmental landscape.

The cardiovascular disorders segment is expected to grow at a considerable CAGR between 2026 and 2035. This is due to the surging cases of cardiovascular diseases in various nations, such as France, Qatar, China, and Brazil. Oligonucleotide-based treatments, such as antisense therapies, can specifically modulate genes involved in cholesterol metabolism, blood clotting, and other cardiovascular pathways, offering more precise and effective interventions than traditional drugs. Additionally, the rapid investment by the governments of several countries in opening new cardiovascular treatment centers is expected to accelerate the growth of this segment.

Company Size Insights

Why Did the Large and Very Large Segment Dominate the Oligonucleotide Synthesis Market?

The large and very large segment dominated the market with the largest share in 2025. This is due to the surging investment by large pharmaceutical companies in developing advanced technologies to accelerate the drug discovery process. Moreover, partnerships among large biopharmaceutical companies and chemical brands to develop new therapeutics for treating rare diseases have boosted the growth of this segment.

The mid-sized segment is expected to grow with a robust CAGR during the forecast period. This is mainly due to the increasing focus of the mid-sized biopharmaceutical companies to enhance research and development of oligonucleotide therapeutics for treating cancers. Unlike smaller firms, they can scale production and meet regulatory standards, while being more flexible than large corporations in adopting innovative synthesis methods and customized solutions. Additionally, mid-sized biotech and pharmaceutical companies are increasingly focusing on niche therapeutic areas, such as rare diseases and personalized medicine, driving demand for tailored oligonucleotide products.

Type of Oligonucleotide Synthesized Insights

What Made Antisense Oligonucleotide the Leading Segment in Market?

The antisense oligonucleotide segment led the oligonucleotide synthesis market in 2025. This is due to the increased use of antisense oligonucleotides to treat a wide range of diseases by binding to specific RNA sequences. Additionally, numerous applications of antisense oligonucleotides, such as RNA degradation, splice modulation, inhibiting infectious diseases, and targeting genetic diseases, have driven the growth of this segment.

The siRNA segment is expected to grow with a notable CAGR during the forecast period. This is owing to the growing use of siRNA for gene expression and enhancing gene slicing capabilities. Moreover, several advantages of siRNA, including high specificity, superior potency, and enhanced versatility, are expected to propel the growth of this segment.

Scale of Operation Insights

Why Did the Commercial Segment Dominate the Oligonucleotide Synthesis Market?

The commercial segment dominated the oligonucleotide synthesis market in 2025 and is expected to grow significantly during the forecast period. This is because large-scale production enables consistent quality, higher throughput, and cost efficiency, meeting the growing demand from pharmaceutical, biotech, and research organizations. Commercial manufacturers can provide standardized, ready-to-use oligonucleotides, reducing development time for end users and ensuring regulatory compliance. Additionally, the increasing adoption of oligonucleotide-based therapeutics, diagnostics, and personalized medicine solutions globally has driven preference for reliable commercial sources over small-scale or in-house synthesis.

End-Users Insights

What Made Pharmaceutical/Biopharmaceutical Companies the Dominant Segment in the Market?

The pharmaceutical/biopharmaceutical companies segment dominated the oligonucleotide synthesis market in 2025. This is due to the rapid investment by the pharmaceutical companies in opening new production centers in various nations, such as the U.S., China, and India. Also, the growing emphasis of the biopharma companies on manufacturing high-quality medicines to treat liver disorders has fostered the growth of this segment.

The hospitals segment is expected to grow at a notable rate due to the increasing use of oligonucleotide-based diagnostics and therapies for personalized patient care. Hospitals are adopting these products for rapid genetic testing, rare disease detection, and targeted treatments, which improve clinical outcomes and support precision medicine initiatives. Additionally, the rise in chronic and genetic disorders has increased demand for hospital-based applications, where ready-to-use oligonucleotides streamline workflow and reduce turnaround time.

Regional Insights

North America Oligonucleotide Synthesis Market Size and Growth 2026 to 2035

The North America oligonucleotide synthesis market size is estimated at USD 2.16 billion in 2025 and is projected to reach approximately USD 5.63 billion by 2035, with a 10.05% CAGR from 2026 to 2035.

Why Did North America Dominate the Oligonucleotide Synthesis Market?

North America dominated the oligonucleotide synthesis market by holding a major share in 2025. This is due to the increased prevalence of prostate cancer in numerous countries, such as Canada, the U.S., and Mexico. Also, numerous government initiatives aimed at strengthening the pharmaceutical sector, along with constant R&D activities related to oligonucleotide synthesis, are playing a vital role in shaping the industrial landscape. Moreover, investments and business expansions by several market players, such as Agilent Technologies, Thermo Fisher Scientific, and TriLink Biotechnologies, have driven the growth of the oligonucleotide synthesis market in this region.

• In August 2025, Thermo Fisher Scientific opened a new innovative manufacturing centre of excellence in North Carolina, U.S. This production center was inaugurated to develop a wide range of therapeutics in this country.

U.S. Oligonucleotide Synthesis Market Size and Growth 2026 to 2035

The U.S. oligonucleotide synthesis market size is calculated at USD 1.62 billion in 2025 and is expected to reach nearly USD 4.25 billion in 2035, accelerating at a strong CAGR of 10.13% between 2026 and 2035.

U.S. Oligonucleotide Synthesis Industry Trends

The U.S. is a major contributor to the oligonucleotide synthesis market in North America. This is due to the surging focus of the pharmaceutical companies in developing advanced therapeutics for treating genetic disorders, as well as technological advancements in the biotech sector. Additionally, the growing demand for oligonucleotide therapeutics from public hospitals is contributing significantly to the industry.

Why is Asia Pacific Expanding with the Fastest CAGR in the Market?

Asia Pacific is expected to expand with the fastest CAGR during the forecast period. This is owing to the growing cases of genetic disorders in several countries, such as China, Japan, India, Australia, and South Korea. Also, the rise in the number of pharma-based startups, coupled with the surging investment in the pharma sector by government organizations, is playing a vital role in shaping the industry in a positive direction. Moreover, product launches and collaborations by numerous market players, such as Sumitomo Chemical, GenScript Biotech Corp, Ajinomoto Bio-Pharma Services, and Bioserve India, are expected to drive the growth of the oligonucleotide synthesis market in this region.

• In October 2025, Ajinomoto Bio-Pharma Services collaborated with Gene Tools, LLC. This collaboration aims at developing a wide range of oligonucleotide therapeutics for the treatment of genetic disorders.

China Oligonucleotide Synthesis Industry Analysis

China is the major contributor to the oligonucleotide synthesis market within Asia Pacific. This is due to the increasing prevalence of heart diseases, coupled with the rise in the number of medical research centers. Additionally, the rapid deployment of advanced technologies in the biopharmaceutical production centers, to enhance the production of high-quality therapeutics, is positively contributing to the industry.

Oligonucleotide Synthesis Market Companies

• Agilent Technologies
• Ajinomoto Bio-Pharma Services
• CordenPharma
• Creative Biolabs
• Ella Biotech
• Eurofins Genomics
• Future synthesis
• Integrated DNA Technologies
• Kaneka Eurogentec
• LGC Biosearch Technologies
• Merck
• STA Pharmaceutical/Wuxi STA
• Sumitomo Chemical
• Thermo Fisher Scientific
• TriLink Biotechnologies
• Microsynth
• Nitto Avecia
• Ribo Biotechnology

Segments Covered in the Report

By Type of Product Synthesized

• Active Pharmaceutical Ingredients
• Finished Dosage Forms

By Type of Oligonucleotide Synthesized

• Antisense
• DNA
• siRNA
• Other Oligonucleotides

By Company Size

• Small
• Mid-sized
• Large and Very Large

By Scale of Operation

• Clinical
• Commercial

By Therapeutic Area

• Cardiovascular Disorders
• Genetic Disorders
• Liver Disorders
• Rare Diseases
• Other Disorders

By End-Users

• Pharmaceutical/Biopharmaceutical Companies
• Academic and Research Institutes
• Hospitals

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa